# Eli Lilly and Company quarterly revenue

entity: /record/eli-lilly.md  
predicate: quarterly_revenue  
page: /record/eli-lilly/quarterly_revenue  
as_of: 2026-11-10  
cite: AsOf. "Eli Lilly and Company quarterly revenue: 24,397,000,000 United States dollar", as of 2026-09-30. Claim clm_E1B01E0405B5, https://asof.is/claim/clm_E1B01E0405B5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.  

As of November 10, 2026, Eli Lilly and Company's quarterly revenue on the AsOf record is $24.4 billion, dated September 30, 2026, from a primary source (sec.gov).

56 claims on Eli Lilly and Company's quarterly revenue, 1 open and 55 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted.

## Current quarterly revenue

What the record asserts on 2026-11-10.

- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 24,397,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_E1B01E0405B5](/claim/clm_E1B01E0405B5.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm

## Every dated value

One claim per line, oldest first. Superseded claims stay visible.

- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,150,400,000 United States dollar | valid 2008-06-30 to 2008-09-30 | conf 0.95 | superseded | superseded_by [clm_FC4E2F880E31](/claim/clm_FC4E2F880E31.md) | [clm_1102EFDDC838](/claim/clm_1102EFDDC838.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,209,500,000 United States dollar | valid 2008-09-30 to 2009-03-31 | conf 0.95 | superseded | superseded_by [clm_59E4AE9C36CB](/claim/clm_59E4AE9C36CB.md) | [clm_FC4E2F880E31](/claim/clm_FC4E2F880E31.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,047,000,000 United States dollar | valid 2009-03-31 to 2009-06-30 | conf 0.95 | superseded | superseded_by [clm_7DCE73A04E98](/claim/clm_7DCE73A04E98.md) | [clm_59E4AE9C36CB](/claim/clm_59E4AE9C36CB.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,292,800,000 United States dollar | valid 2009-06-30 to 2009-09-30 | conf 0.95 | superseded | superseded_by [clm_DC9E250C63CB](/claim/clm_DC9E250C63CB.md) | [clm_7DCE73A04E98](/claim/clm_7DCE73A04E98.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,562,000,000 United States dollar | valid 2009-09-30 to 2010-03-31 | conf 0.95 | superseded | superseded_by [clm_8F20DCC9E865](/claim/clm_8F20DCC9E865.md) | [clm_DC9E250C63CB](/claim/clm_DC9E250C63CB.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,485,500,000 United States dollar | valid 2010-03-31 to 2010-06-30 | conf 0.95 | superseded | superseded_by [clm_A35F7484BB60](/claim/clm_A35F7484BB60.md) | [clm_8F20DCC9E865](/claim/clm_8F20DCC9E865.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,748,700,000 United States dollar | valid 2010-06-30 to 2010-09-30 | conf 0.95 | superseded | superseded_by [clm_4D8CE841EAC1](/claim/clm_4D8CE841EAC1.md) | [clm_A35F7484BB60](/claim/clm_A35F7484BB60.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310070596/0000950123-10-070596-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,654,800,000 United States dollar | valid 2010-09-30 to 2011-03-31 | conf 0.95 | superseded | superseded_by [clm_D8537173D284](/claim/clm_D8537173D284.md) | [clm_4D8CE841EAC1](/claim/clm_4D8CE841EAC1.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310097867/0000950123-10-097867-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,839,200,000 United States dollar | valid 2011-03-31 to 2011-06-30 | conf 0.95 | superseded | superseded_by [clm_DC301C0F7A36](/claim/clm_DC301C0F7A36.md) | [clm_D8537173D284](/claim/clm_D8537173D284.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000119312511117877/0001193125-11-117877-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,252,800,000 United States dollar | valid 2011-06-30 to 2011-09-30 | conf 0.95 | superseded | superseded_by [clm_8942550E1D13](/claim/clm_8942550E1D13.md) | [clm_DC301C0F7A36](/claim/clm_DC301C0F7A36.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000119312511202740/0001193125-11-202740-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,147,900,000 United States dollar | valid 2011-09-30 to 2012-03-31 | conf 0.95 | superseded | superseded_by [clm_7903628E4764](/claim/clm_7903628E4764.md) | [clm_8942550E1D13](/claim/clm_8942550E1D13.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000119312511286084/0001193125-11-286084-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,602,000,000 United States dollar | valid 2012-03-31 to 2012-06-30 | conf 0.95 | superseded | superseded_by [clm_5DAD0E6A0EE5](/claim/clm_5DAD0E6A0EE5.md) | [clm_7903628E4764](/claim/clm_7903628E4764.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000119312512195656/0001193125-12-195656-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,600,700,000 United States dollar | valid 2012-06-30 to 2012-09-30 | conf 0.95 | superseded | superseded_by [clm_911654133F1A](/claim/clm_911654133F1A.md) | [clm_5DAD0E6A0EE5](/claim/clm_5DAD0E6A0EE5.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947812000006/0000059478-12-000006-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,443,300,000 United States dollar | valid 2012-09-30 to 2013-03-31 | conf 0.95 | superseded | superseded_by [clm_0690B5F615D3](/claim/clm_0690B5F615D3.md) | [clm_911654133F1A](/claim/clm_911654133F1A.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947812000021/0000059478-12-000021-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,602,000,000 United States dollar | valid 2013-03-31 to 2013-06-30 | conf 0.95 | superseded | superseded_by [clm_3FC6922ADF8C](/claim/clm_3FC6922ADF8C.md) | [clm_0690B5F615D3](/claim/clm_0690B5F615D3.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947813000019/0000059478-13-000019-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,929,700,000 United States dollar | valid 2013-06-30 to 2013-09-30 | conf 0.95 | superseded | superseded_by [clm_843FCDB40589](/claim/clm_843FCDB40589.md) | [clm_3FC6922ADF8C](/claim/clm_3FC6922ADF8C.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947813000043/0000059478-13-000043-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,772,600,000 United States dollar | valid 2013-09-30 to 2014-03-31 | conf 0.95 | superseded | superseded_by [clm_E805A9930871](/claim/clm_E805A9930871.md) | [clm_843FCDB40589](/claim/clm_843FCDB40589.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947813000057/0000059478-13-000057-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 4,683,100,000 United States dollar | valid 2014-03-31 to 2014-06-30 | conf 0.95 | superseded | superseded_by [clm_104129ED0A97](/claim/clm_104129ED0A97.md) | [clm_E805A9930871](/claim/clm_E805A9930871.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947814000102/0000059478-14-000102-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 4,935,600,000 United States dollar | valid 2014-06-30 to 2014-09-30 | conf 0.95 | superseded | superseded_by [clm_19B3061EB704](/claim/clm_19B3061EB704.md) | [clm_104129ED0A97](/claim/clm_104129ED0A97.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947814000129/0000059478-14-000129-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 4,875,600,000 United States dollar | valid 2014-09-30 to 2015-03-31 | conf 0.95 | superseded | superseded_by [clm_5E48B7152576](/claim/clm_5E48B7152576.md) | [clm_19B3061EB704](/claim/clm_19B3061EB704.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947814000169/0000059478-14-000169-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 4,644,700,000 United States dollar | valid 2015-03-31 to 2015-06-30 | conf 0.95 | superseded | superseded_by [clm_F15C91D955BE](/claim/clm_F15C91D955BE.md) | [clm_5E48B7152576](/claim/clm_5E48B7152576.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947815000132/0000059478-15-000132-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 4,978,700,000 United States dollar | valid 2015-06-30 to 2015-09-30 | conf 0.95 | superseded | superseded_by [clm_AED191B23B0D](/claim/clm_AED191B23B0D.md) | [clm_F15C91D955BE](/claim/clm_F15C91D955BE.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947815000164/0000059478-15-000164-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 4,959,700,000 United States dollar | valid 2015-09-30 to 2016-03-31 | conf 0.95 | superseded | superseded_by [clm_1F4EC3A3B4D5](/claim/clm_1F4EC3A3B4D5.md) | [clm_AED191B23B0D](/claim/clm_AED191B23B0D.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947815000175/0000059478-15-000175-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 4,865,100,000 United States dollar | valid 2016-03-31 to 2016-06-30 | conf 0.95 | superseded | superseded_by [clm_72B1497E5670](/claim/clm_72B1497E5670.md) | [clm_1F4EC3A3B4D5](/claim/clm_1F4EC3A3B4D5.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947816000353/0000059478-16-000353-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,404,800,000 United States dollar | valid 2016-06-30 to 2016-09-30 | conf 0.95 | superseded | superseded_by [clm_ADD269D8EB64](/claim/clm_ADD269D8EB64.md) | [clm_72B1497E5670](/claim/clm_72B1497E5670.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,191,700,000 United States dollar | valid 2016-09-30 to 2017-03-31 | conf 0.95 | superseded | superseded_by [clm_038044B3B9B8](/claim/clm_038044B3B9B8.md) | [clm_ADD269D8EB64](/claim/clm_ADD269D8EB64.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947816000440/0000059478-16-000440-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,228,300,000 United States dollar | valid 2017-03-31 to 2017-06-30 | conf 0.95 | superseded | superseded_by [clm_1D6AC1DB5DDA](/claim/clm_1D6AC1DB5DDA.md) | [clm_038044B3B9B8](/claim/clm_038044B3B9B8.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947817000129/0000059478-17-000129-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,824,300,000 United States dollar | valid 2017-06-30 to 2017-09-30 | conf 0.95 | superseded | superseded_by [clm_5FD91BF932E6](/claim/clm_5FD91BF932E6.md) | [clm_1D6AC1DB5DDA](/claim/clm_1D6AC1DB5DDA.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/0000059478-17-000183-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,658,000,000 United States dollar | valid 2017-09-30 to 2018-03-31 | conf 0.95 | superseded | superseded_by [clm_2064AA6387A6](/claim/clm_2064AA6387A6.md) | [clm_5FD91BF932E6](/claim/clm_5FD91BF932E6.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947817000204/0000059478-17-000204-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,700,000,000 United States dollar | valid 2018-03-31 to 2018-06-30 | conf 0.95 | superseded | superseded_by [clm_F2315229046E](/claim/clm_F2315229046E.md) | [clm_2064AA6387A6](/claim/clm_2064AA6387A6.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947818000136/0000059478-18-000136-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,355,200,000 United States dollar | valid 2018-06-30 to 2018-09-30 | conf 0.95 | superseded | superseded_by [clm_FE144E331568](/claim/clm_FE144E331568.md) | [clm_F2315229046E](/claim/clm_F2315229046E.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947818000188/0000059478-18-000188-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,061,900,000 United States dollar | valid 2018-09-30 to 2019-03-31 | conf 0.95 | superseded | superseded_by [clm_596A387D969F](/claim/clm_596A387D969F.md) | [clm_FE144E331568](/claim/clm_FE144E331568.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947818000256/0000059478-18-000256-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,092,200,000 United States dollar | valid 2019-03-31 to 2019-06-30 | conf 0.95 | superseded | superseded_by [clm_F113B6E2585B](/claim/clm_F113B6E2585B.md) | [clm_596A387D969F](/claim/clm_596A387D969F.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947819000174/0000059478-19-000174-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,636,700,000 United States dollar | valid 2019-06-30 to 2019-09-30 | conf 0.95 | superseded | superseded_by [clm_645E82FC1A32](/claim/clm_645E82FC1A32.md) | [clm_F113B6E2585B](/claim/clm_F113B6E2585B.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947819000232/0000059478-19-000232-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,476,600,000 United States dollar | valid 2019-09-30 to 2020-03-31 | conf 0.95 | superseded | superseded_by [clm_C179CB065205](/claim/clm_C179CB065205.md) | [clm_645E82FC1A32](/claim/clm_645E82FC1A32.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947819000278/0000059478-19-000278-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,859,800,000 United States dollar | valid 2020-03-31 to 2020-06-30 | conf 0.95 | superseded | superseded_by [clm_DFC5FB76B4A1](/claim/clm_DFC5FB76B4A1.md) | [clm_C179CB065205](/claim/clm_C179CB065205.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947820000104/0000059478-20-000104-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,499,400,000 United States dollar | valid 2020-06-30 to 2020-09-30 | conf 0.95 | superseded | superseded_by [clm_66B1C3D114E4](/claim/clm_66B1C3D114E4.md) | [clm_DFC5FB76B4A1](/claim/clm_DFC5FB76B4A1.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947820000131/0000059478-20-000131-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 5,740,600,000 United States dollar | valid 2020-09-30 to 2021-03-31 | conf 0.95 | superseded | superseded_by [clm_97459A7EC040](/claim/clm_97459A7EC040.md) | [clm_66B1C3D114E4](/claim/clm_66B1C3D114E4.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947820000155/0000059478-20-000155-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,805,600,000 United States dollar | valid 2021-03-31 to 2021-06-30 | conf 0.95 | superseded | superseded_by [clm_77D077A608D2](/claim/clm_77D077A608D2.md) | [clm_97459A7EC040](/claim/clm_97459A7EC040.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947821000122/0000059478-21-000122-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,740,100,000 United States dollar | valid 2021-06-30 to 2021-09-30 | conf 0.95 | superseded | superseded_by [clm_E26527683C4E](/claim/clm_E26527683C4E.md) | [clm_77D077A608D2](/claim/clm_77D077A608D2.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947821000171/0000059478-21-000171-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,772,800,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_DB3AB0C80149](/claim/clm_DB3AB0C80149.md) | [clm_E26527683C4E](/claim/clm_E26527683C4E.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947821000216/0000059478-21-000216-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 7,810,000,000 United States dollar | valid 2022-03-31 to 2022-06-30 | conf 0.95 | superseded | superseded_by [clm_5B96A4E73738](/claim/clm_5B96A4E73738.md) | [clm_DB3AB0C80149](/claim/clm_DB3AB0C80149.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,488,000,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_E29C4C5B9DDD](/claim/clm_E29C4C5B9DDD.md) | [clm_5B96A4E73738](/claim/clm_5B96A4E73738.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947822000196/0000059478-22-000196-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,941,600,000 United States dollar | valid 2022-09-30 to 2023-03-31 | conf 0.95 | superseded | superseded_by [clm_CC9DB32026CE](/claim/clm_CC9DB32026CE.md) | [clm_E29C4C5B9DDD](/claim/clm_E29C4C5B9DDD.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 6,960,000,000 United States dollar | valid 2023-03-31 to 2023-06-30 | conf 0.95 | superseded | superseded_by [clm_D152AA3878B8](/claim/clm_D152AA3878B8.md) | [clm_CC9DB32026CE](/claim/clm_CC9DB32026CE.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947823000162/0000059478-23-000162-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 8,312,100,000 United States dollar | valid 2023-06-30 to 2023-09-30 | conf 0.95 | superseded | superseded_by [clm_3A1E7B4FAF72](/claim/clm_3A1E7B4FAF72.md) | [clm_D152AA3878B8](/claim/clm_D152AA3878B8.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 9,498,600,000 United States dollar | valid 2023-09-30 to 2024-03-31 | conf 0.95 | superseded | superseded_by [clm_1AD340C3A5DB](/claim/clm_1AD340C3A5DB.md) | [clm_3A1E7B4FAF72](/claim/clm_3A1E7B4FAF72.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947823000284/0000059478-23-000284-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 8,768,000,000 United States dollar | valid 2024-03-31 to 2024-06-30 | conf 0.95 | superseded | superseded_by [clm_3E94821DE7E1](/claim/clm_3E94821DE7E1.md) | [clm_1AD340C3A5DB](/claim/clm_1AD340C3A5DB.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947824000118/0000059478-24-000118-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 11,302,800,000 United States dollar | valid 2024-06-30 to 2024-09-30 | conf 0.95 | superseded | superseded_by [clm_0D9BE0B6BA02](/claim/clm_0D9BE0B6BA02.md) | [clm_3E94821DE7E1](/claim/clm_3E94821DE7E1.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947824000187/0000059478-24-000187-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 11,439,100,000 United States dollar | valid 2024-09-30 to 2025-03-31 | conf 0.95 | superseded | superseded_by [clm_684F3B3B6CFA](/claim/clm_684F3B3B6CFA.md) | [clm_0D9BE0B6BA02](/claim/clm_0D9BE0B6BA02.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947824000245/0000059478-24-000245-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 12,728,500,000 United States dollar | valid 2025-03-31 to 2025-06-30 | conf 0.95 | superseded | superseded_by [clm_7CBD9D7BE5AE](/claim/clm_7CBD9D7BE5AE.md) | [clm_684F3B3B6CFA](/claim/clm_684F3B3B6CFA.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/0000059478-25-000132-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 15,557,700,000 United States dollar | valid 2025-06-30 to 2025-09-30 | conf 0.95 | superseded | superseded_by [clm_D3881089FBD6](/claim/clm_D3881089FBD6.md) | [clm_7CBD9D7BE5AE](/claim/clm_7CBD9D7BE5AE.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947825000204/0000059478-25-000204-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 17,600,800,000 United States dollar | valid 2025-09-30 to 2026-03-31 | conf 0.95 | superseded | superseded_by [clm_DF742A5515B7](/claim/clm_DF742A5515B7.md) | [clm_D3881089FBD6](/claim/clm_D3881089FBD6.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 19,799,000,000 United States dollar | valid 2026-03-31 to 2026-06-30 | conf 0.95 | superseded | superseded_by [clm_D2C1E8A7329C](/claim/clm_D2C1E8A7329C.md) | [clm_DF742A5515B7](/claim/clm_DF742A5515B7.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/0000059478-26-000045-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 22,974,000,000 United States dollar | valid 2026-06-30 to 2026-09-30 | conf 0.95 | superseded | superseded_by [clm_E1B01E0405B5](/claim/clm_E1B01E0405B5.md) | [clm_D2C1E8A7329C](/claim/clm_D2C1E8A7329C.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/0000059478-26-000081-index.htm
- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_revenue | 24,397,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_E1B01E0405B5](/claim/clm_E1B01E0405B5.md)
  sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm

## What replaced what

- $5.15 billion (2008-06-30 to 2008-09-30, [clm_1102EFDDC838](/claim/clm_1102EFDDC838.md)) was replaced by $5.21 billion from 2008-09-30 ([clm_FC4E2F880E31](/claim/clm_FC4E2F880E31.md))
- $5.21 billion (2008-09-30 to 2009-03-31, [clm_FC4E2F880E31](/claim/clm_FC4E2F880E31.md)) was replaced by $5.05 billion from 2009-03-31 ([clm_59E4AE9C36CB](/claim/clm_59E4AE9C36CB.md))
- $5.05 billion (2009-03-31 to 2009-06-30, [clm_59E4AE9C36CB](/claim/clm_59E4AE9C36CB.md)) was replaced by $5.29 billion from 2009-06-30 ([clm_7DCE73A04E98](/claim/clm_7DCE73A04E98.md))
- $5.29 billion (2009-06-30 to 2009-09-30, [clm_7DCE73A04E98](/claim/clm_7DCE73A04E98.md)) was replaced by $5.56 billion from 2009-09-30 ([clm_DC9E250C63CB](/claim/clm_DC9E250C63CB.md))
- $5.56 billion (2009-09-30 to 2010-03-31, [clm_DC9E250C63CB](/claim/clm_DC9E250C63CB.md)) was replaced by $5.49 billion from 2010-03-31 ([clm_8F20DCC9E865](/claim/clm_8F20DCC9E865.md))
- $5.49 billion (2010-03-31 to 2010-06-30, [clm_8F20DCC9E865](/claim/clm_8F20DCC9E865.md)) was replaced by $5.75 billion from 2010-06-30 ([clm_A35F7484BB60](/claim/clm_A35F7484BB60.md))
- $5.75 billion (2010-06-30 to 2010-09-30, [clm_A35F7484BB60](/claim/clm_A35F7484BB60.md)) was replaced by $5.65 billion from 2010-09-30 ([clm_4D8CE841EAC1](/claim/clm_4D8CE841EAC1.md))
- $5.65 billion (2010-09-30 to 2011-03-31, [clm_4D8CE841EAC1](/claim/clm_4D8CE841EAC1.md)) was replaced by $5.84 billion from 2011-03-31 ([clm_D8537173D284](/claim/clm_D8537173D284.md))
- $5.84 billion (2011-03-31 to 2011-06-30, [clm_D8537173D284](/claim/clm_D8537173D284.md)) was replaced by $6.25 billion from 2011-06-30 ([clm_DC301C0F7A36](/claim/clm_DC301C0F7A36.md))
- $6.25 billion (2011-06-30 to 2011-09-30, [clm_DC301C0F7A36](/claim/clm_DC301C0F7A36.md)) was replaced by $6.15 billion from 2011-09-30 ([clm_8942550E1D13](/claim/clm_8942550E1D13.md))
- $6.15 billion (2011-09-30 to 2012-03-31, [clm_8942550E1D13](/claim/clm_8942550E1D13.md)) was replaced by $5.6 billion from 2012-03-31 ([clm_7903628E4764](/claim/clm_7903628E4764.md))
- $5.6 billion (2012-03-31 to 2012-06-30, [clm_7903628E4764](/claim/clm_7903628E4764.md)) was replaced by $5.6 billion from 2012-06-30 ([clm_5DAD0E6A0EE5](/claim/clm_5DAD0E6A0EE5.md))
- $5.6 billion (2012-06-30 to 2012-09-30, [clm_5DAD0E6A0EE5](/claim/clm_5DAD0E6A0EE5.md)) was replaced by $5.44 billion from 2012-09-30 ([clm_911654133F1A](/claim/clm_911654133F1A.md))
- $5.44 billion (2012-09-30 to 2013-03-31, [clm_911654133F1A](/claim/clm_911654133F1A.md)) was replaced by $5.6 billion from 2013-03-31 ([clm_0690B5F615D3](/claim/clm_0690B5F615D3.md))
- $5.6 billion (2013-03-31 to 2013-06-30, [clm_0690B5F615D3](/claim/clm_0690B5F615D3.md)) was replaced by $5.93 billion from 2013-06-30 ([clm_3FC6922ADF8C](/claim/clm_3FC6922ADF8C.md))
- $5.93 billion (2013-06-30 to 2013-09-30, [clm_3FC6922ADF8C](/claim/clm_3FC6922ADF8C.md)) was replaced by $5.77 billion from 2013-09-30 ([clm_843FCDB40589](/claim/clm_843FCDB40589.md))
- $5.77 billion (2013-09-30 to 2014-03-31, [clm_843FCDB40589](/claim/clm_843FCDB40589.md)) was replaced by $4.68 billion from 2014-03-31 ([clm_E805A9930871](/claim/clm_E805A9930871.md))
- $4.68 billion (2014-03-31 to 2014-06-30, [clm_E805A9930871](/claim/clm_E805A9930871.md)) was replaced by $4.94 billion from 2014-06-30 ([clm_104129ED0A97](/claim/clm_104129ED0A97.md))
- $4.94 billion (2014-06-30 to 2014-09-30, [clm_104129ED0A97](/claim/clm_104129ED0A97.md)) was replaced by $4.88 billion from 2014-09-30 ([clm_19B3061EB704](/claim/clm_19B3061EB704.md))
- $4.88 billion (2014-09-30 to 2015-03-31, [clm_19B3061EB704](/claim/clm_19B3061EB704.md)) was replaced by $4.64 billion from 2015-03-31 ([clm_5E48B7152576](/claim/clm_5E48B7152576.md))
- $4.64 billion (2015-03-31 to 2015-06-30, [clm_5E48B7152576](/claim/clm_5E48B7152576.md)) was replaced by $4.98 billion from 2015-06-30 ([clm_F15C91D955BE](/claim/clm_F15C91D955BE.md))
- $4.98 billion (2015-06-30 to 2015-09-30, [clm_F15C91D955BE](/claim/clm_F15C91D955BE.md)) was replaced by $4.96 billion from 2015-09-30 ([clm_AED191B23B0D](/claim/clm_AED191B23B0D.md))
- $4.96 billion (2015-09-30 to 2016-03-31, [clm_AED191B23B0D](/claim/clm_AED191B23B0D.md)) was replaced by $4.87 billion from 2016-03-31 ([clm_1F4EC3A3B4D5](/claim/clm_1F4EC3A3B4D5.md))
- $4.87 billion (2016-03-31 to 2016-06-30, [clm_1F4EC3A3B4D5](/claim/clm_1F4EC3A3B4D5.md)) was replaced by $5.4 billion from 2016-06-30 ([clm_72B1497E5670](/claim/clm_72B1497E5670.md))
- $5.4 billion (2016-06-30 to 2016-09-30, [clm_72B1497E5670](/claim/clm_72B1497E5670.md)) was replaced by $5.19 billion from 2016-09-30 ([clm_ADD269D8EB64](/claim/clm_ADD269D8EB64.md))
- $5.19 billion (2016-09-30 to 2017-03-31, [clm_ADD269D8EB64](/claim/clm_ADD269D8EB64.md)) was replaced by $5.23 billion from 2017-03-31 ([clm_038044B3B9B8](/claim/clm_038044B3B9B8.md))
- $5.23 billion (2017-03-31 to 2017-06-30, [clm_038044B3B9B8](/claim/clm_038044B3B9B8.md)) was replaced by $5.82 billion from 2017-06-30 ([clm_1D6AC1DB5DDA](/claim/clm_1D6AC1DB5DDA.md))
- $5.82 billion (2017-06-30 to 2017-09-30, [clm_1D6AC1DB5DDA](/claim/clm_1D6AC1DB5DDA.md)) was replaced by $5.66 billion from 2017-09-30 ([clm_5FD91BF932E6](/claim/clm_5FD91BF932E6.md))
- $5.66 billion (2017-09-30 to 2018-03-31, [clm_5FD91BF932E6](/claim/clm_5FD91BF932E6.md)) was replaced by $5.7 billion from 2018-03-31 ([clm_2064AA6387A6](/claim/clm_2064AA6387A6.md))
- $5.7 billion (2018-03-31 to 2018-06-30, [clm_2064AA6387A6](/claim/clm_2064AA6387A6.md)) was replaced by $6.36 billion from 2018-06-30 ([clm_F2315229046E](/claim/clm_F2315229046E.md))
- $6.36 billion (2018-06-30 to 2018-09-30, [clm_F2315229046E](/claim/clm_F2315229046E.md)) was replaced by $6.06 billion from 2018-09-30 ([clm_FE144E331568](/claim/clm_FE144E331568.md))
- $6.06 billion (2018-09-30 to 2019-03-31, [clm_FE144E331568](/claim/clm_FE144E331568.md)) was replaced by $5.09 billion from 2019-03-31 ([clm_596A387D969F](/claim/clm_596A387D969F.md))
- $5.09 billion (2019-03-31 to 2019-06-30, [clm_596A387D969F](/claim/clm_596A387D969F.md)) was replaced by $5.64 billion from 2019-06-30 ([clm_F113B6E2585B](/claim/clm_F113B6E2585B.md))
- $5.64 billion (2019-06-30 to 2019-09-30, [clm_F113B6E2585B](/claim/clm_F113B6E2585B.md)) was replaced by $5.48 billion from 2019-09-30 ([clm_645E82FC1A32](/claim/clm_645E82FC1A32.md))
- $5.48 billion (2019-09-30 to 2020-03-31, [clm_645E82FC1A32](/claim/clm_645E82FC1A32.md)) was replaced by $5.86 billion from 2020-03-31 ([clm_C179CB065205](/claim/clm_C179CB065205.md))
- $5.86 billion (2020-03-31 to 2020-06-30, [clm_C179CB065205](/claim/clm_C179CB065205.md)) was replaced by $5.5 billion from 2020-06-30 ([clm_DFC5FB76B4A1](/claim/clm_DFC5FB76B4A1.md))
- $5.5 billion (2020-06-30 to 2020-09-30, [clm_DFC5FB76B4A1](/claim/clm_DFC5FB76B4A1.md)) was replaced by $5.74 billion from 2020-09-30 ([clm_66B1C3D114E4](/claim/clm_66B1C3D114E4.md))
- $5.74 billion (2020-09-30 to 2021-03-31, [clm_66B1C3D114E4](/claim/clm_66B1C3D114E4.md)) was replaced by $6.81 billion from 2021-03-31 ([clm_97459A7EC040](/claim/clm_97459A7EC040.md))
- $6.81 billion (2021-03-31 to 2021-06-30, [clm_97459A7EC040](/claim/clm_97459A7EC040.md)) was replaced by $6.74 billion from 2021-06-30 ([clm_77D077A608D2](/claim/clm_77D077A608D2.md))
- $6.74 billion (2021-06-30 to 2021-09-30, [clm_77D077A608D2](/claim/clm_77D077A608D2.md)) was replaced by $6.77 billion from 2021-09-30 ([clm_E26527683C4E](/claim/clm_E26527683C4E.md))
- $6.77 billion (2021-09-30 to 2022-03-31, [clm_E26527683C4E](/claim/clm_E26527683C4E.md)) was replaced by $7.81 billion from 2022-03-31 ([clm_DB3AB0C80149](/claim/clm_DB3AB0C80149.md))
- $7.81 billion (2022-03-31 to 2022-06-30, [clm_DB3AB0C80149](/claim/clm_DB3AB0C80149.md)) was replaced by $6.49 billion from 2022-06-30 ([clm_5B96A4E73738](/claim/clm_5B96A4E73738.md))
- $6.49 billion (2022-06-30 to 2022-09-30, [clm_5B96A4E73738](/claim/clm_5B96A4E73738.md)) was replaced by $6.94 billion from 2022-09-30 ([clm_E29C4C5B9DDD](/claim/clm_E29C4C5B9DDD.md))
- $6.94 billion (2022-09-30 to 2023-03-31, [clm_E29C4C5B9DDD](/claim/clm_E29C4C5B9DDD.md)) was replaced by $6.96 billion from 2023-03-31 ([clm_CC9DB32026CE](/claim/clm_CC9DB32026CE.md))
- $6.96 billion (2023-03-31 to 2023-06-30, [clm_CC9DB32026CE](/claim/clm_CC9DB32026CE.md)) was replaced by $8.31 billion from 2023-06-30 ([clm_D152AA3878B8](/claim/clm_D152AA3878B8.md))
- $8.31 billion (2023-06-30 to 2023-09-30, [clm_D152AA3878B8](/claim/clm_D152AA3878B8.md)) was replaced by $9.5 billion from 2023-09-30 ([clm_3A1E7B4FAF72](/claim/clm_3A1E7B4FAF72.md))
- $9.5 billion (2023-09-30 to 2024-03-31, [clm_3A1E7B4FAF72](/claim/clm_3A1E7B4FAF72.md)) was replaced by $8.77 billion from 2024-03-31 ([clm_1AD340C3A5DB](/claim/clm_1AD340C3A5DB.md))
- $8.77 billion (2024-03-31 to 2024-06-30, [clm_1AD340C3A5DB](/claim/clm_1AD340C3A5DB.md)) was replaced by $11.3 billion from 2024-06-30 ([clm_3E94821DE7E1](/claim/clm_3E94821DE7E1.md))
- $11.3 billion (2024-06-30 to 2024-09-30, [clm_3E94821DE7E1](/claim/clm_3E94821DE7E1.md)) was replaced by $11.44 billion from 2024-09-30 ([clm_0D9BE0B6BA02](/claim/clm_0D9BE0B6BA02.md))
- $11.44 billion (2024-09-30 to 2025-03-31, [clm_0D9BE0B6BA02](/claim/clm_0D9BE0B6BA02.md)) was replaced by $12.73 billion from 2025-03-31 ([clm_684F3B3B6CFA](/claim/clm_684F3B3B6CFA.md))
- $12.73 billion (2025-03-31 to 2025-06-30, [clm_684F3B3B6CFA](/claim/clm_684F3B3B6CFA.md)) was replaced by $15.56 billion from 2025-06-30 ([clm_7CBD9D7BE5AE](/claim/clm_7CBD9D7BE5AE.md))
- $15.56 billion (2025-06-30 to 2025-09-30, [clm_7CBD9D7BE5AE](/claim/clm_7CBD9D7BE5AE.md)) was replaced by $17.6 billion from 2025-09-30 ([clm_D3881089FBD6](/claim/clm_D3881089FBD6.md))
- $17.6 billion (2025-09-30 to 2026-03-31, [clm_D3881089FBD6](/claim/clm_D3881089FBD6.md)) was replaced by $19.8 billion from 2026-03-31 ([clm_DF742A5515B7](/claim/clm_DF742A5515B7.md))
- $19.8 billion (2026-03-31 to 2026-06-30, [clm_DF742A5515B7](/claim/clm_DF742A5515B7.md)) was replaced by $22.97 billion from 2026-06-30 ([clm_D2C1E8A7329C](/claim/clm_D2C1E8A7329C.md))
- $22.97 billion (2026-06-30 to 2026-09-30, [clm_D2C1E8A7329C](/claim/clm_D2C1E8A7329C.md)) was replaced by $24.4 billion from 2026-09-30 ([clm_E1B01E0405B5](/claim/clm_E1B01E0405B5.md))

## Questions this record answers

### What is Eli Lilly and Company's current quarterly revenue?

$24.4 billion, dated September 30, 2026, from a primary source (sec.gov). The record asserts this claim as of November 10, 2026 (status valid, confidence 0.95).

### When did Eli Lilly and Company's quarterly revenue last change?

The latest value on the record is $24.4 billion, dated September 30, 2026; before it the record holds $22.97 billion, dated June 30, 2026 and closed on September 30, 2026.

### What was Eli Lilly and Company's quarterly revenue before $24.4 billion?

$22.97 billion, valid from June 30, 2026 to September 30, 2026 (status superseded), from a primary source (sec.gov).


## Read on

- This page: /record/eli-lilly/quarterly_revenue (markdown: /record/eli-lilly/quarterly_revenue.md)
- Entity twin: /record/eli-lilly.md · timeline: /timelines/eli-lilly.md
- Every company's quarterly revenue: /facts/quarterly_revenue.md

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.